Andrew Saul Artz MD MS

Hematologic Oncology

Professor of Hematology and Hematopoietic Cell Transplantation City of Hope

1500 Duarte RdDuarte, CA 91010
Phone+1 626-256-4673
Fax+1 626-408-3911

Dr. Artz is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Artz's full profile Already have an account?

Summary

Dr. Andrew Artz is an hematologist/oncologist based in Duarte, CA, specializing in blood disorders and allogeneic stem cell transplant. He completed his medical education at West Virginia University School of Medicine in 1997, followed by a residency in internal medicine at Georgetown University and a fellowship in hematology and medical oncology the University of Chicago, respectively. He also obtained a masters degree in health studies at university of Chicago and completed a visiting transplant fellowship at Fred Hutchinson in Seattle, Washington. Dr. Artz held academic appointments at the University of Chicago Medical Center from 2005 to 2019, progressing from instructor to associate professor. Dr. Artz is now a professor of Hematology and HCT at City of Hope in Duarte California where he also serves as Director of the Aging and Blood Cancer program and deputy Director of Health Outcomes for the Center for Cancer and Aging. He is seasoned clinician in hematologic oncology managing great Acute Leukemias, MDS, anemia, and stem cell transplantation. Dr. Artz has an active research profile with publications and international leadership related to blood disorders in older adults. He has an active research portfolio of clinical trials and health outcomes research.

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2001 - 2004
MedStar Health Georgetown University/Georgetown HospitalResidency, Internal Medicine, 1997 - 2000
West Virginia University School of MedicineClass of 1997

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

IL State Medical License 2000 - 2029
CA State Medical License 2019 - 2027
DC State Medical License 1999 - 2002
VA State Medical License 1998 - 2002
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017
CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017

Clinical Trials

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
COMPLETED
PHASE2
Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes Start of enrollment: 2008 Oct 02
UNKNOWN
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
ACTIVE_NOT_RECRUITING
PHASE3

Publications & Presentations

PubMed

Implementing CHARM in transplant practice.
Mohamed L Sorror, Andrew Artz
Blood Advances. 2026-08-11
Hypomethylating agents-venetoclax as salvage therapy for relapse of AML and MDS after allogeneic HCT.
Diana T Samuels, Brian J Ball, Ni-Chun Tsai, Salman Otoukesh, Shukaib Arslan
Blood Neoplasia. 2026-08-01
Clinical Implications of CD19-Negative Relapse Following CD19-Directed Therapy in B-Cell Acute Lymphoblastic Leukemia.
Tamer Othman, Vaibhav Agrawal, Joo Y Song, Zhaohui Gu, Paul Koller
American Journal of Hematology. 2026-07-23

Abstracts/Posters

Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A...
Andrew S. Artz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors
Andrew S. Artz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS
Andrew S. Artz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Adult and Pediatric BMT
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: A Systematic Review with a Specific Focus o...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Age Is Just a Number: Blood Cancer Care in Older PatientsAugust 14th, 2025
City of Hope Doctors and Scientists Present Research on Novel Cancer Therapies at American Society of Hematology (ASH) Annual ConferenceDecember 10th, 2024
City of Hope Researchers Present Innovative Studies at American Society of Hematology (ASH) Annual MeetingDecember 13th, 2022